Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,153.1
-4.8 (-0.15%)

 

  • STI Straits Times Index
    3,153.1
    -4.8 (-0.15%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,582.5
    7.3 (0.46%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    28,738.9
    -
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,610.9
    -
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,161.8
    213.1 (0.74%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,080.4
    -15.1 (-0.25%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 2,126.6M
  • Value: 940.1M
  • Rise: 187
  • Fall: 160
  • Unch: 415

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
AMOS0.024+0.002
RH PetroGas0.200+0.076
MarcoPolo Marine0.029+0.003
GSS Energy0.082+0.019
Metal Component0.071+0.005
Kim Heng0.096+0.018
MM2 Asia0.070-0.004
Mermaid Maritime0.090+0.020
Interra Resource^0.047+0.010
AusGroup0.029+0.002

World Indices

World Indices
Name Last Change
Nasdaq 14,069.4 +49.1
HSI 28,738.9
HSCEI 10,716.3
Jakarta 6,080.4 -15.1
Nikkei 225 29,161.8 +213.1
SSE Comp 3,610.9
Shanghai A 3,784.8
Shanghai B 257.5
KOSPI 3,252.1 +2.8

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

IX Biopharma IX BIOPHARMA LTD.
Quotes 10 Minutes Delayed. Updated at 14 Jun 2021 17:04
Last (SGD): 0.245 Change: +0.005 High: 0.245 Remarks: -
Change (%): +2.08 Low: 0.235
Open 0.235 Yesterday's Close 0.240
Buy Price 0.240 Sell Price 0.245
Buy Volume ('000) 645.6 Sell Volume ('000) 330.3
Cumulative Volume ('000) 2,682.1 Cumulative Value 647,714
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a -0.01507 Trailing EPS (SGD) e -0.01083 NAV (SGD) b 0.0236
PE a - Trailing PE f - Price / NAV b 10.3814
Dividend (SGD) d - Cash In Hand (SGD) g 0.0136 Issued & Paid-up Shares c 696,853,000
Dividend Yield (%) d - Price / Cash In Hand g 18.015 Treasury Shares h -
Beta - 75 Daysi 0.122 R-Squared - 75 Days(%)i 0.09 Market Cap (M) 170.729
Beta - 500 Daysi 0.512 R-Squared - 500 Days (%)i 1.38 Enterprise Value (M) 165.199
Piotroski F Score 1 Exchange Code 42C Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 49.1513 6-Month VWAP 0.252 Free Float (%) 51.3
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Prof, Scientific & Technical Activities - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Index Components FTSE ST Catalist Index
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 10 Feb 2021.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference IX Biopharma SGX 170.729 - - 10.3814 -
Industry Medical & Biotechnology SGX 971.365 19.896 16.872 1.3856 2.033
Pharmaceuticals: Major SGX 92.144 2431.015 115.115 3.6851 0.674
Index FTSE ST Catalist Index SGX 67.936 129.441 59.926 1.6056 1.525
Local Peer Hyphens Pharma SGX 100.644 16.333 16.330 2.1338 1.851
Local Peer Pharmesis Intl SGX 5.060 - - 0.4441 -
Global Peer JOHNSON & JOHNSON NYSE 434,405.664 29.523 28.740 6.5985 2.412
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 228,671.791 28.161 28.653 4.5261 2.052
Global Peer PFIZER INC NYSE 224,747.253 23.372 20.264 3.2753 3.790
Global Peer ELI LILLY AND COMPANY NYSE 214,908.136 34.698 35.274 31.1522 1.318
Global Peer ABBVIE INC NYSE 203,857.112 44.745 40.098 14.8693 4.191
Global Peer MERCK & CO INC NYSE 193,120.216 27.327 27.479 7.1672 3.249
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NASDAQ 154,302.986 47.907 38.533 10.6932 2.331
Global Peer BRISTOL-MYERS SQUIBB CO NYSE 150,432.846 - - 4.0003 2.745
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 149,692.692 23.230 22.267 16.1934 1.593
Global Peer SANOFI SPON ADR ECH REP 0.5 ORD SHS NASDAQ 135,660.466 9.664 9.664 1.7599 2.491
Other Global Peers GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 (NYSE), WUXI APPTEC (HKEx), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), ROYALTY PHARMA PLC (NASDAQ), HANSOH PHARMA (HKEx), VIATRIS INC (NASDAQ), CUREVAC NV (NASDAQ), INNOVENT BIO (HKEx), CANSINOBIO-B (HKEx), REPLIGEN CORP (NASDAQ), SINOPHARM (HKEx), JUNSHI BIO (HKEx), REMEGEN-B (HKEx), ORGANON & CO (NYSE), HYGEIA HEALTH (HKEx), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), CMS (HKEx), AKESO-B (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), SH PHARMA (HKEx), IMMUNITYBIO INC (NASDAQ), I MAB SPON ADS EACH REP 2.3 ORD SHS (NASDAQ), LEGEND BIOTECH CORP SPON ADS EACH REP 2 ORD SHS (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), INNOCARE-B (HKEx), ALLAKOS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), BAIYUNSHAN PH (HKEx), HUTCHMED (CHINA) LIMITED SPON ADS EACH REPR 5 ORD SHS (NASDAQ), CHINARES PHARMA (HKEx), SIMCERE PHARMA (HKEx), SPRINGWORKS THERAPEUTICS INC (NASDAQ), KARUNA THERAPEUTICS INC (NASDAQ), TURNING POINT THERAPEUTICS INC (NASDAQ), CHINAGRANDPHARM (HKEx), EMERGENT BIOSOLUTIONS INC (NYSE), TRAD CHI MED (HKEx), NEKTAR THERAPEUTICS (NASDAQ), IGM BIOSCIENCES INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), HENLIUS (HKEx), EVEREST MED-B (HKEx), OPKO HEALTH INC (NASDAQ), OCUMENSION-B (HKEx), QUANTERIX CORPORATION (NASDAQ), CSTONE PHARMA-B (HKEx), HEPALINK (HKEx), SSY GROUP (HKEx), ATEA PHARMACEUTICALS INC (NASDAQ), CENTESSA PHARMACEUTICALS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), HARMONY BIOSCIENCES HLDGS INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), ZYMEWORKS INC (NYSE), CEREVEL THERAPEUTICS HLDGS INC (NASDAQ), ADC THERAPEUTICS SA (NYSE), BROOKLYN IMMUNO THERAPEUTICS INC (NYSE American), UNITED LAB (HKEx), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), Y-MABS THERAPEUTICS INC (NASDAQ), GENERATION BIO CO (NASDAQ), KRONOS BIO INC (NASDAQ), ANTENGENE-B (HKEx), KRYSTAL BIOTECH INC (NASDAQ), ARCUTIS BIOTHERAPEUTICS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), CULLINAN ONCOLOGY INC (NASDAQ), IMMUNOTECH-B (HKEx), MIND MEDICINE (MINDMED) INC (NASDAQ), TONGRENTANGCM (HKEx), NURIX THERAPEUTICS INC (NASDAQ), ALIGOS THERAPEUTICS INC (NASDAQ), SCICLONE PHARMA (HKEx), DAY ONE BIOPHARMACEUTICALS INC (NASDAQ), REPARE THERAPEUTICS INC (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), KEROS THERAPEUTICS INC (NASDAQ), SILVERBACK THERAPEUTICS INC (NASDAQ), OLEMA PHARMACEUTICALS INC (NASDAQ), PETIQ INC (NASDAQ), CKLIFE SCIENCES (HKEx), OCULAR THERAPEUTIX INC (NASDAQ), PHATHOM PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), FORMA THERAPEUTICS HLDGS INC (NASDAQ), KINNATE BIOPHARMA INC (NASDAQ), Kimia Farma Tbk. (IDX), KINIKSA PHARMACEUTICALS LTD (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), CONNECT BIOPHARMA HLDGS LTD ADS EACH REP ONE ORD SHARE (NASDAQ), ANNEXON INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), NRX PHARMACEUTICALS INC (NASDAQ), PRAXIS PRECISION MEDICINES INC (NASDAQ), ZHAOKE OPHTH-B (HKEx), SUTRO BIOPHARMA INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), SHINEWAY PHARM (HKEx), CALLIDITAS THERAPEUTICS AB SPON ADS EACH REP 2 ORD SHS (NASDAQ), CHINOOK THERAPEUTICS INC (NASDAQ), TARSUS PHARMACEUTICALS INC (NASDAQ), ANNOVIS BIO INC (NYSE American), ORIC PHARMACEUTICALS INC (NASDAQ), VERU INC (NASDAQ), KALVISTA PHARMACEUTICALS INC (NASDAQ), TALARIS THERAPEUTICS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), EVOLUS INC (NASDAQ), CLENE INC (NASDAQ), PHARVARIS NV (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), BOLT BIOTHERAPEUTICS INC (NASDAQ), BIOMEA FUSION INC (NASDAQ), CODIAK BIOSCIENCES INC (NASDAQ), ADAGENE INC SPON ADS EACH REP 1.25 ORD SHS (NASDAQ), VECTIVBIO HLDG AG (NASDAQ), AC IMMUNE SA (NASDAQ), HUA MEDICINE-B (HKEx), NANOBIOTIX S A SPON ADS EACH REP 1 ORD SHS (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), MIRUM PHARMACEUTICALS INC (NASDAQ), VACCITECH PLC ADR EACH REPR 1 ORD SH SPON (NASDAQ), RELMADA THERAPEUTICS INC (NASDAQ), PROVENTION BIO INC (NASDAQ), ACHILLES THERAPEUTICS PLC ADS EACH REPR 1 SHARE SPON (NASDAQ), SIGA TECHNOLOGIES INC (NASDAQ), GRITSTONE BIO INC (NASDAQ), OYSTER POINT PHARMA INC (NASDAQ), Soho Global Health Tbk. (IDX), IGBB (Bursa), ATHENEX INC (NASDAQ), SPERO THERAPEUTICS INC (NASDAQ), BEYONDSPRING INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), RACE ONCOLOGY LTD (ASX), AMRYT PHARMA PLC (NEW) SPON ADS EACH REP 5 ORD SHS (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), ANGION BIOMEDICA CORP (NASDAQ), DURECT CORP (NASDAQ), INOZYME PHARMA INC (NASDAQ), 89BIO INC (NASDAQ), NEXIMMUNE INC (NASDAQ), GAMIDA CELL LTD (NASDAQ), XOMA CORP (NASDAQ), CITIUS PHARMACEUTICALS INC (NASDAQ), FUSION PHARMACEUTICALS INC (NASDAQ), FUSEN PHARM (HKEx), DAWNRAYS PHARMA (HKEx), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), THERATECHNOLOGIES INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), TOT BIOPHARM-B (HKEx), MUSTANG BIO INC (NASDAQ), PHARMA (Bursa), ORPHAZYME A/S SPON ADS REP 1 ORD SHS (NASDAQ), NAVIDEA BIOPHARMACEUTICALS INC (NYSE American), IMMUNIC INC (NASDAQ), TFF PHARMACEUTICALS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), BSTEAD (Bursa), RENEO PHARMACEUTICALS INC (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), KALEIDO BIOSCIENCES INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), 4D PHARMA PLC SPONS ADR EACH REP 8 ORD SHS (NASDAQ), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), ONCTERNAL THERAPEUTICS INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), TRICIDA INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), VINCERX PHARMA INC (NASDAQ), GALERA THERAPEUTICS INC (NASDAQ), IMPEL NEUROPHARMA INC (NASDAQ), HARROW HEALTH INC (NASDAQ), NOVAN INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), LANNETT CO INC (NYSE), VYNE THERAPEUTICS INC (NASDAQ), CH BIOTECH SER (HKEx), IP (SET), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), 180 LIFE SCIENCES CORP (NASDAQ), ANEBULO PHARMACEUTICALS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), LANTERN PHARMA INC (NASDAQ), POLYPID LTD (NASDAQ), GENPREX INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), ETON PHARMACEUTICALS INC (NASDAQ), YUMANITY THERAPEUTICS INC (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), QILIAN INTERNATIONAL HLDG GROUP LTD (NASDAQ), SATSUMA PHARMACEUTICALS INC (NASDAQ), ZHONGZHIPHARM (HKEx), CRESO PHARMA LTD (ASX), SCPHARMACEUTICALS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), NOXOPHARM LTD (ASX), IMARA INC (NASDAQ), ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ), LOGICBIO THERAPEUTICS INC (NASDAQ), AYALA PHARMACEUTICALS INC (NASDAQ), ODONATE THERAPEUTICS INC (NASDAQ), GALECTO INC (NASDAQ), LIQUIDIA CORPORATION (NASDAQ), EYENOVIA INC (NASDAQ), F-STAR THERAPEUTICS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), AYTU BIOPHARMA INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), ELEDON PHARMACEUTICALS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), GRAYBUG VISION INC (NASDAQ), MEDIWOUND LTD (NASDAQ), LYRA THERAPEUTICS INC (NASDAQ), Merck Tbk. (IDX), PROTARA THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), APREA THERAPEUTICS INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), AERPIO PHARMACEUTICALS INC (NASDAQ), PROPHASE LABS INC (NASDAQ), ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 6 ORD SHS (NASDAQ), NEW RAY MEDIC (HKEx), CHARMACY PHAR (HKEx), ENTERA BIO LTD (NASDAQ), PURPLE BIOTECH LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), KOTRA (Bursa), NC HEALTHCARE (HKEx), ASSERTIO HOLDINGS INC (NASDAQ), EXOPHARM LTD (ASX), ARIDIS PHARMACEUTICAL INC (NASDAQ), EDESA BIOTECH INC (NASDAQ), MODERN CHI MED (HKEx), PAK FAH YEOW (HKEx), Phapros Tbk. (IDX), ALLENA PHARMACEUTICALS INC (NASDAQ), BAUDAX BIO INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), DARE BIOSCIENCE INC (NASDAQ), OCUPHIRE PHARMA INC (NASDAQ), INVION LTD (ASX), NOVA (Bursa), UNIVERSE PHARMACEUTICALS INC (NASDAQ), BIOHLDG (Bursa), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), BRICKELL BIOTECH INC (NASDAQ), INHIBIKASE THERAPEUTICS INC (NASDAQ), WAI YUEN TONG (HKEx), AGEX THERAPEUTICS INC (NYSE American), NEP INTERLONG (HKEx), TELIGENT INC NEW (NASDAQ), MANNATECH INC (NASDAQ), VIRIOS THERAPEUTICS INC (NASDAQ), CNS PHARMACEUTICALS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), TIMBER PHARMACEUTICALS INC (NYSE American), EXTRAWELL PHAR (HKEx), PALLA PHARMA LTD (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), TBG DIAGNOSTICS LTD (ASX), MEDLAB CLINICAL LIMITED (ASX), REVIVA PHARMACEUTICALS HOLDINGS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), NLS PHARMACEUTICS LTD (NASDAQ), PANBELA THERAPEUTICS INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), HOTH THERAPEUTICS INC (NASDAQ), SANAI HEALTH GP (HKEx), SUNZEN (Bursa), PURAPHARM (HKEx), JCT (SET), VALLON PHARMACEUTICALS INC (NASDAQ), PETROS PHARMACEUTICALS INC (NASDAQ), PAINREFORM LTD (NASDAQ), SYNAPTOGENIX INC (NASDAQ), IMMURON LIMITED (ASX), PHARMAXIS (ASX), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), ACRUX (ASX), MILLENDO THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), CHINA SXT PHARMACEUTICALS INC (NASDAQ), SINOLIFE UTD (HKEx), VIRPAX PHARMA INC (NASDAQ), TALI DIGITAL LIMITED (ASX), ISLAND PHARMACEUTICALS LTD (ASX), PASHUN INT'L (HKEx), SUDA PHARMACEUTICALS LTD (ASX), FIJI KAVA LTD (ASX), CELLMID LIMITED (ASX), FARMAFORCE LTD (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days ---
20 Days --0.005
-2.00 %
Medium Term Return 3 Months -+0.005
+2.08 %
6 Months ---
1 Year -+0.005
+2.08 %
Long Term Return 2 Years -+0.015
+6.52 %
3 Years -+0.075
+44.12 %
5 Years --0.076
-23.68 %
Annualised Return Annualised --
-5.26 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.210 - 0.350 Change From 1 Year Low +0.035 % Change From 1 Year Low (%) +16.67
Change From 1 Year High -0.105 % Change From 1 Year High (%) -30.00
2 Years Range 0.130 - 0.350 Change From 2 Years Low +0.115 % Change From 2 Years Low (%) +88.46
Change From 2 Years High -0.105 % Change From 2 Years High (%) -30.00
5 Years Range 0.130 - 0.380 Change From 5 Years Low +0.115 % Change From 5 Years Low (%) +88.46
Change From 5 Years High -0.135 % Change From 5 Years High (%) -35.53
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

iX Biopharma is a specialty pharmaceutical and nutraceutical company listed on the Catalist board of the Singapore Exchange Securities Trading Limited (SGX-ST), operating a fully integrated business model from drug development to manufacturing and supply, with facilities in Australia. The Group is focused on the development and commercialisation of therapies for diseases of the central nervous system using novel, patent-protected formulations for sublingual delivery. iX Biopharma’s pipeline of products under development includes Wafermine (ketamine wafer) and BnoX (buprenorphine wafer) for pain management. iX Biopharma’s drugs for the treatment of erectile dysfunction, Wafesil, a sublingual sildenafil wafer, and Silcap, have been registered in Australia. iX Biopharma has developed Xativa, the world’s first freeze-dried sublingual medicinal cannabis wafer. The Group’s nutraceuticals division, Entity Health Limited, is engaged in the development and commercialisation of nutraceutical products that address specific conditions and improve quality of life. It distributes its Entity line of nutraceutical products in Australia through more than 250 pharmacies and health food shops, in China through its flagship stores on Tmall Global and JD Worldwide, and globally through its online store.

IPO Performance

Listing Date 22 Jul 2015 Full Subscription Rate (x) 1.36
No of Placement Shares (M) 64.50 No of Public Offer Shares (M) 1.00 Public Offer Subscription Rate (x) 24.65
IPO Price (SGD) a 0.454 First Day Close (SGD) a 0.552 First Week Close (SGD) a 0.414
Current vs IPO Price (%) -46.04 First Day Gain (%) +21.59 First Week Gain (%) -8.81
Notes:
  1. Adjusted for the following: Rights Issue 1 for 25 @ $0.21 on 22/06/2016

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2020 Jun 2020 Part 1(4.14 MB)
Annual Report 2019 Jun 2019 Part 1(4.31 MB)
Annual Report 2018 Jun 2018 Part 1(6.28 MB)
Annual Report 2017 Jun 2017 Part 1(1.40 MB)
Annual Report 2016 Jun 2016 Part 1(4.32 MB)
Part 2(0.12 MB)
Annual Report 2015 Jun 2015 Part 1(0.59 MB)
IPO Prospectus
IPO Prospectus 2015 Jul 2015 Part 1(3.65 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
14 Jun 2021 0.235 0.245 0.235 0.245 2,682,100 0.2415
11 Jun 2021 0.240 0.240 0.235 0.240 291,400 0.2357
10 Jun 2021 0.235 0.240 0.235 0.235 1,118,700 0.2361
09 Jun 2021 0.235 0.240 0.235 0.235 1,870,500 0.2353
08 Jun 2021 0.245 0.245 0.240 0.245 522,200 0.2430
07 Jun 2021 0.245 0.245 0.240 0.245 739,300 0.2445
04 Jun 2021 0.235 0.245 0.235 0.245 5,363,500 0.2410
03 Jun 2021 0.245 0.245 0.235 0.235 1,396,800 0.2414
02 Jun 2021 0.245 0.245 0.240 0.240 2,732,300 0.2428
01 Jun 2021 0.245 0.245 0.235 0.235 338,000 0.2407
31 May 2021 0.240 0.245 0.235 0.245 1,853,400 0.2423
28 May 2021 0.240 0.240 0.235 0.240 107,300 0.2353
27 May 2021 0.235 0.240 0.235 0.235 170,800 0.2356
25 May 2021 0.230 0.235 0.230 0.235 442,300 0.2340
24 May 2021 0.235 0.235 0.225 0.225 1,036,600 0.2298
21 May 2021 0.230 0.235 0.230 0.235 600,500 0.2333
20 May 2021 0.235 0.235 0.230 0.230 327,600 0.2327
19 May 2021 0.240 0.240 0.230 0.235 737,300 0.2351
18 May 2021 0.245 0.250 0.235 0.235 9,992,200 0.2454
17 May 2021 0.235 0.255 0.235 0.250 9,059,800 0.2485
14 May 2021 0.240 0.240 0.220 0.220 2,039,000 0.2296
12 May 2021 0.240 0.240 0.235 0.235 218,300 0.2366
Summary
Current 2 Weeks
(01 Jun 2021 to 14 Jun 2021)
0.245 0.245 0.235 0.245 17,054,800 -
Previous 2 Weeks
(17 May 2021 to 31 May 2021)
0.235 0.255 0.235 0.245 24,327,800 -
4 Weeks from
(16 Apr 2021 to 14 May 2021)
0.245 0.245 0.235 0.220 17,390,900 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.